Beyond the EVS: Is it Time for a New Paradigm in Endophthalmitis Management?
Exogenous endophthalmitis remains a devastating complication of intraocular procedures, despite the steady decline in infection rates over the last two decades. For nearly 30 years, our clinical decision-making has been anchored by the Endophthalmitis Vitrectomy Study (EVS), published in 1995. However, as we navigate an era of rapid technological advancement, many in the retina community are asking: Is it time to move past the EVS?
The Waning Applicability of a 30-Year-Old Gold Standard
The EVS established the benchmark that patients with light perception (LP) vision or worse benefit from prompt vitrectomy, while others require only a vitreous tap and antibiotic injection. While foundational, the study has several limitations for the modern surgeon:
- Outdated Surgical Context: The EVS focused on acute endophthalmitis after cataract surgery using techniques from the early 1990s. Today, we use foldable lenses, smaller wounds, valved trocars, and intracameral antibiotics.
- Shifting Inciting Procedures: Intravitreal injections have supplanted cataract surgery as the most common intraocular procedure in some studies. The EVS guidelines may not directly apply to post-injection endophthalmitis or cases involving trauma and glaucoma surgery.
- Poor Antibiotic Penetration: The EVS found no benefit for systemic antibiotics, but it utilized agents with poor intraocular penetration (amikacin and ceftazidime). Modern fluoroquinolones offer much better penetration, potentially augmenting intravitreal therapy.
A Global Divergence in Practice
Current practice patterns show a significant departure from EVS recommendations. In the United States, an IRIS® Registry analysis revealed that only 34.2% of patients with LP vision after cataract surgery underwent the recommended vitrectomy. This may be due to logistical hurdles, such as limited after-hours access at ambulatory surgery centers and the geographic scarcity of vitreoretinal surgeons in rural areas.
In contrast, European practice has diverged in the opposite direction, with 74.3% of patients undergoing vitrectomy within one week of presentation, regardless of their initial visual acuity. This global lack of consensus reflects a broadening discontent with current algorithms.
New Frontiers: Pathogen-Informed Treatment and Host Response
The future of endophthalmitis care likely lies in tailored, pathogen-centric approaches. Standard microbiology only identifies organisms in 40% to 70% of cases and takes days to yield results. Emerging sequencing strategies offer higher detection rates and can identify virulent copathogens that require more aggressive intervention.
Furthermore, we are learning that visual outcomes are dictated not just by the bacteria, but by the host immune response and bacterial toxins. Key insights include:
- Virulence Matters: Infections from Streptococcus or Enterococcus often result in poor outcomes due to direct toxin damage and profound inflammation.
- Adjunctive Therapy: While intravitreal steroids have shown mixed results, the use of oral corticosteroids has been found to reduce the risk of globe loss.
- Early Intervention: Recent trials suggest that early vitrectomy (within 24 hours) may lead to faster visual recovery and better final outcomes compared to a vitreous tap.
Conclusion: A Call for Innovation
The limited arsenal of “tap or vitrectomy” may no longer be sufficient for our most difficult cases. With the expansion of rapid sequencing, more powerful antibiotics, and targeted anti-inflammatory agents, we have the tools to rethink our approach. The time has come to work toward a modern treatment algorithm that accounts for pathogen virulence and the host’s inflammatory response to save more eyes from this catastrophic condition.
Reference:
http://doi.org/10.1016/j.ophtha.2026.02.016 ISSN 0161-6420/26
